• Recruiting

NCT04721002: Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)

NCT04721002: Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) (MEDICI)

AbbVie t11;14 myeloma

NCT04721002: Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) (MEDICI)


Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and relapsed/refractory (R/R) MM.


Sponsor

AbbVie

 

ClinicalTrials.gov Identifier: NCT04721002

Official Title: MEDICI - t(11;14) and BCL2 Expression in Patients With Multiple Myeloma: Prevalence, Stability Across Lines of Therapy and Concordance Across Sample Types

First Posted : January 22, 2021

Click here for details on ClinicalTrials.gov

 

Location

United States, Louisiana

United States, Texas

South America

Argentina

Brazil

Australia, Victoria

Canada, Alberta

Europe

Asia

Croatia

Czechia

France

Germany

Greece

Ireland

Israel

Italy

Netherlands

Norway

Poland

Romania

Saudi Arabia

Slovenia

Spain

Taiwan

Turkey


Posts Archive